In Vitro Antitubercular Activity of Pippalyadi Avaleha

Abstract

In Ayurvedic medicine, Pippalyadi Avaleha is a traditional polyherbal formulation that has been studied for its potential anti-tubercular properties. The primary component, Piper longum (Pippali), is known for its immunomodulatory, anti-inflammatory, and bronchodilator effects, which are beneficial in managing respiratory conditions like TB. Pippalyadi Avaleha is believed to enhance pulmonary function, modulate the immune response, and provide symptomatic relief in TB patients. Integrating Pippalyadi Avaleha into a multidisciplinary treatment regimen may offer complementary benefits, particularly in cases of multidrug-resistant TB. The pharmacological actions of this Ayurvedic formulation, including its ability to enhance host immunity and reduce pulmonary inflammation, support its use as an adjunct therapy in TB management. This approach aligns with the need for novel treatments that can address drug-resistant TB strains while supporting overall patient health. Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a serious infectious disease that primarily targets the lungs but can disseminate to other organs. The increasing incidence of multidrug-resistant TB (MDR-TB) poses a significant challenge to conventional treatment, necessitating the exploration of alternative therapeutic approaches.